Our Technology and Invention Led to Breakthrough in Effective Treatment of the Deadliest Pancreatic Cancer 

We showed that Magnetoelectric Nanoparticles (MENPs), when activated by a magnetic field, provide a minimally invasive, drug-free, effective theranostic (diagnose and treat at the same time) treatment to the most deadly form of pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) which has the lowest survival rate among all cancers.

Experiments at NCI Moffitt Cancer Center on PDAC xenograft mice showed that a single MENP treatment achieved a threefold median reduction in tumor volume and complete tumor responses in 33.3% of mice at 300 and 600 µg doses (N = 17) and significantly longer mean overall survival as compared to the control cohorts (54.1 vs 28.8 days, χ2 = 40.14, p = 0.045), without evident toxicity in any imaged organ. In contrast, mice receiving subtherapeutic doses, non-activated MENPs, or saline controls showed no significant response. 

The context is there is no effective treatment to PDAC as of now and PDAC patients' five-year survival rate is only 8%. 

This treatment is applicable to many other types of hard-to-treat cancers, and survival rate and complete response rate should increase from repeated treatments.

Read the full paper on Advanced Science: Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models